The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.
Yung-Jue Bang
Disclosure not yet available
Wu-Chou Su
Disclosure not yet available
Do-Hyun Nam
Disclosure not yet available
Wan-Teck Lim
Disclosure not yet available
Todd Michael Bauer
Disclosure not yet available
Irene Brana
Disclosure not yet available
Ronnie Tung-Ping Poon
Disclosure not yet available
David S. Hong
Disclosure not yet available
Chia-Chi Lin
Disclosure not yet available
Bin Peng
Disclosure not yet available
Yingxi Zhang
Disclosure not yet available
Sylvia Zhao
Disclosure not yet available
Arun Kumar
Disclosure not yet available
Mikhail Akimov
Disclosure not yet available
Brigette Ma
Disclosure not yet available